BackTandem Diabetes Care Overview
Tandem Diabetes Care Inc

Tandem Diabetes Care Target Price

Where could TNDM trade next? Consensus target price: $28.

Get informed when a big investor buys or sells

+ Follow

Share Price

$19.9

Average Target Price

$28.3142.3% upside

8 analysts in the last 4 months

High: $55 | Low: $15.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07RBC CapitalKendall Au$2630.7% upsideOpen
2026-08-07Canaccord GenuityWilliam Plovanic$40101% upsideOpen
2026-07-28UBS$189.5% downsideOpen
2026-06-23Deutsche Bank$15.522.1% downsideOpen
2026-06-01Wells Fargo$2735.7% upsideOpen
2026-05-27Goldman Sachs$215.5% upsideOpen
2026-05-11Barclays$55176.4% upsideOpen
2026-05-08Mizuho SecuritiesAnthony Petrone$2420.6% upsideOpen
2026-04-24Redburn PartnersIssie Kirby$45126.1% upsideOpen
2026-02-23Truist Financial$2735.7% upsideOpen
2026-02-23Lake Street$50151.3% upsideOpen
2026-02-23Goldman SachsDavid Roman$2840.7% upsideOpen
2026-02-23BarclaysMatt Miksic$56181.4% upsideOpen
2026-02-20Mizuho Securities$2210.6% upsideOpen
2026-02-20Stifel Nicolaus$2210.6% upsideOpen
2026-02-20UBS$2210.6% upsideOpen
2026-02-20Piper SandlerMatt O'Brien$215.5% upsideOpen
2026-02-04Stifel Nicolaus$200.5% upsideOpen
2026-01-09Goldman SachsDavid Roman$2525.6% upsideOpen
2025-12-18Truist Financial$2420.6% upsideOpen
2025-12-17RBC Capital$3050.8% upsideOpen
2025-12-17Canaccord GenuityWilliam Plovanic$3575.9% upsideOpen
2025-12-17Mizuho SecuritiesAnthony Petrone$215.5% upsideOpen
2025-12-16Robert W. Baird$3050.8% upsideOpen
2025-12-02Morgan Stanley$2315.6% upsideOpen
2025-10-15Truist FinancialRichard Newitter$1619.6% downsideOpen
2025-09-08OppenheimerSuraj Kalia$2210.6% upsideOpen
2025-08-07Canaccord GenuityWilliam Plovanic$2420.6% upsideOpen
2025-08-07Piper SandlerMatt O'Brien$1429.6% downsideOpen
2025-03-05Morgan Stanley$2210.6% upsideOpen
2025-02-28Bernstein$2525.6% upsideOpen
2025-02-28Barclays$53166.3% upsideOpen
2025-01-08BernsteinLee Hambright$44121.1% upsideOpen
2024-11-07Robert W. BairdJeff Johnson$3785.9% upsideOpen
2024-11-05BernsteinLee Hambright$42111.1% upsideOpen
2024-10-04Goldman SachsDavid Roman$46131.2% upsideOpen
2024-10-02RBC CapitalShagun Singh$65226.6% upsideOpen
2024-08-08Canaccord GenuityWilliam Plovanic$57186.4% upsideOpen
2024-08-05BarclaysMatt Miksic$58191.5% upsideOpen
2024-08-02Piper SandlerMatt O'Brien$55176.4% upsideOpen
2024-08-02Robert W. BairdJeff Johnson$3996% upsideOpen
2024-06-10OppenheimerSteven Lichtman$58191.5% upsideOpen
2024-05-29Stifel NicolausMatthew Blackman$60201.5% upsideOpen
2024-05-22Lake StreetBrooks O'Neil$75276.9% upsideOpen
2024-05-03Piper SandlerMatt O'Brien$50151.3% upsideOpen
2024-05-03Robert W. BairdJeff Johnson$3680.9% upsideOpen
2024-04-29Wells FargoLawrence Biegelsen$45126.1% upsideOpen
2024-04-25Leerink PartnersDanielle AntalffyMike Kratky$45126.1% upsideOpen
2024-04-22Stifel NicolausMatthew Blackman$40101% upsideOpen
2024-04-11CFRAKenneth Leon$3680.9% upsideOpen

Tandem Diabetes Care (TNDM) FAQ

As of the most recent data, TNDM shows a target price of $28. Scroll down for historical charts and peer comparison views.

If Tandem Diabetes Care moved to the average analyst target of $28, shares would be roughly 42.3% higher than $19.9. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Tandem Diabetes Care's earnings trajectory.

Besides this target price page, Stockcircle has Tandem Diabetes Care's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $28) with ownership activity and broader fundamentals.

Tandem Diabetes Care's target price is $28; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.